ADMA Biologics Inc
NASDAQ:ADMA
ADMA Biologics Inc
Total Current Liabilities
ADMA Biologics Inc
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADMA Biologics Inc
NASDAQ:ADMA
|
Total Current Liabilities
$53.1m
|
CAGR 3-Years
36%
|
CAGR 5-Years
45%
|
CAGR 10-Years
29%
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is ADMA Biologics Inc's Total Current Liabilities?
Total Current Liabilities
53.1m
USD
Based on the financial report for Mar 31, 2024, ADMA Biologics Inc's Total Current Liabilities amounts to 53.1m USD.
What is ADMA Biologics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
29%
Over the last year, the Total Current Liabilities growth was 45%. The average annual Total Current Liabilities growth rates for ADMA Biologics Inc have been 36% over the past three years , 45% over the past five years , and 29% over the past ten years .